This peer-reviewed paper presents solutions to alleviate health system capacity constraints for retinal care.
Impact assessments help funders and health research organizations evaluate progress and performance of their investments and optimize plans for long-term success.
The report is informed by the findings from a national survey of life sciences organizations and focus groups with diverse individuals working in the sector.
We share key insights for pharmaceutical companies bringing new products to the Canadian market, highlighting considerations for the current and future hospital formulary decision-making landscape.
We explore the unique dynamics that colleges must address to establish a competitive edge, present proven and emerging strategies to distinguish research programs, and highlight success stories from the Canadian college ecosystem.
Industry Report: PrEP has tremendous potential across a range of infectious diseases, and innovators need to be ready
To capture opportunities in PrEP beyond HIV, innovators will need to account for unique clinical, commercial and access considerations at the product or portfolio level.
White paper: Unprecedented growth in the life sciences sector is spurring significant demand for wet lab space in the Toronto Region
Toronto Global commissioned Shift Health to conduct stakeholder interviews and secondary research to support the development of a white paper that explores the shortfall of wet lab space in the Toronto Region and details recommendations to catalyze investment and meet demand.
An awakening to systemic racism and harmful colonial structures in the context of a pandemic has made health inequities and injustices impossible to ignore and is driving healthcare organizations to strengthen approaches to inclusion, diversity, equity and accessibility (IDEA). If these efforts are to succeed, we must redefine the competencies that define leadership.
When Decision Meets Precision: Evolving Health Technology Assessments for the Evaluation of Precision Oncology Therapeutics
Expert co-authors examine the opportunity to evolve current HTA approaches for the evaluation of precision oncology therapeutics by extending the window for evidence generation and decision-making to the full lifecycle of a technology.